A man infected with extensively drug-resistant tuberculosis remains in isolation in a Denver hospital, preparing to undergo surgery to treat his illness. One of his doctors discusses plans for treating him, his prognosis, and the state of new drug development for infectious diseases.
Dr. Michael Iseman, former chief, Tuberculosis Program, National Jewish Medical and Research Center; professor of medicine, Divisions of Pulmonary Medicine and Infectious Diseases, University of Colorado
Michael Draper, director, Anti-Infective Drug Discovery, Paratek Pharmaceuticals
Scott Franzblau, professor, Department of Medicinal Chemistry and Pharmacognosy; director, Institute for Tuberculosis Research, University of Illinois at Chicago
Copyright 2023 NPR. To see more, visit https://www.npr.org.
